Serum chemerin and vaspin in non-alcoholic fatty liver disease

Scandinavian Journal of Gastroenterology

Volumn 45, Issue 2, 2010, Pages 235-242

  Kukla, Michal ^a   Zwirska Korczala, Krystyna ^a   Hartleb, Marek ^a   Waluga, Marek ^a   Chwist, Alina ^a   Kajor, MacIej ^a   Ciupinska Kajor, Monika ^a   Berdowska, Agnieszka ^b   Wozniak Grygiel, Elzbieta ^a   Buldak, Rafal ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b Department of Microbiology and Biotechnology   (Poland)

Author keywords

Adipokine; Chemerin; Insulin resistance; Non alcoholic fatty liver disease; Vaspin

Indexed keywords

ADIPOCYTOKINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHEMERIN; CHOLESTEROL; INSULIN; UNCLASSIFIED DRUG; VASPIN;

ADULT; ARTICLE; BODY MASS; CELL DEGENERATION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIVER CELL; LIVER FIBROSIS; LIVER INJURY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STEATOSIS;

ADIPOKINES; ADULT; BIOLOGICAL MARKERS; CHEMOKINES; FATTY LIVER; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; SERPINS;

EID: 76749098030     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365520903443852     Document Type: Article

References (31)

1. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006; 444:847-853
2. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821-1830
3. Bozaoglu K, Bolton K, McMillan J, McMillan J, Zimmet P, Jowett J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007; 148:4687-4694
4. Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC. A novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem 2007;282:28175-28188
5. Moretta A, Marcenaro E, Parolini S, Ferlazzo G, Moretta L. NK cells at the interface between innate and adaptive immunity. Cell Death Differ 2008;15:226-233
6. Yoshimura T, Oppenheim JJ. Chemerin reveals a chimeric nature. JEM 2008;205:2187-2190
7. Cash JL, Hart R, Russ A, Dixon JPC, Colledge WH, Doran J, et al. Synthetic chemerin-derived peptides suppress inflammation through ChemR23. J Exp Med 2008;205:767-775
8. Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med 2008;14:741-751
9. Klöting N, Berndt J, Kralisch S, Kovacs P, Fasshauer M, Schön MR, et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 2006;339:430-436
10. Wada J. Vaspin: a novel serpin with insulin-sensitizing effects. Expert Opin Investig Drugs 2008;17:327-333
11. Gabriel A, Kukla M, Ziolkowski A. Histopathological features and current scoring systems for semiquantitative assessment of nonalcoholic fatty liver disease. Exp Clin Hep 2008;4:RA48-54.
12. Kukla M, Zwirska-Korczala K, Gabriel A, Ziolkowski A, Wylezol M, Berdowska A, et al. Liver tissue alterations in morbidly obese patients undergoing bariatric surgery. Exp Clin Hep 2007;3:OR12-18.
13. Ziolkowski A, Wylezol M, Kukla M, Zwirska-Korczala K, Berdowska A, Paredela M, et al. The comparison of scoring scales for liver biopsy assessment in morbidly obese patients undergoing bariatric surgery. Obes Surg 2005;15:1309-1314
14. Day C, James O. Steatohepatitis: a tale of two "hits". Gastroenterology 1998;114:842-845
15. Carter-Kent C, Zein NN, Feldstein AE. Cytokine in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol 2008;103:1036-1042
16. Bertolani C,Marra F. The role of adipokines in liver fibrosis. Pathophysiology 2008;15:91-101.
17. Williams AL, Hoofangle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 1988;95:734-739
18. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-526
19. Kleiner DE, Brunt EM, Van Natta M, Behling MJ, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321
20. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-a or adiponectin? Hepatology 2004;40:46-54.
21. Roh SG, Song SH, Choi KC, Katoh K, Wittamer V, Parmentier M, et al. Chemerin-a new adipokine that modulates adipogenesis via its own receptor. Biochem Biophys Res Commun 2007;362:1013-1018
22. Takahashi M, Takahashi Y, Takahashi K, Zolotaryov FN, Hong KS, Kitzawa R, et al. Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. FEBS Lett 2008;582:573-578
23. Stejskal D, Karpisek M, Hanulova Z, Svestak M. Chemerin is an independent marker of the metabolic syndrome in a Caucasian population-a pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008;152:217-221
24. Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, et al. Visceral adipose tissue derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 2005;102:10610-10615
25. Youn BS, Klöting N, Kratzsch J, Lee N, Park JW, Song ES, et al. Serum vaspin concentration in human obesity and type 2 diabetes. Diabetes 2008;57:372-377
26. Seeger J, Ziegelmeier M, Bachmann A, Lössner U, Kratzsch J, Blüher M, et al. Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J Clin Endocrinol Metab 2008;93:247-251
27. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27:103-107
28. Powell EE, Cooskley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history on nonalcoholic steatohepatitis: a follow-up study of forty two patients for up to 21 years. Hepatology 1990;11:74-80.
29. Zabel BA, Allen SJ, Kulig P, Allen JA, Cichy J, Handel TM, et al. Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades. J Biol Chem 2005;280:34661-34666
30. Weigert J, Neumeier M, Wanninger J, Filarsky M, Bauer S, Wiest R, et al.Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf) 2009;Jun 24 [Epub ahead of print].
31. Tan BK, Chen J, Farhatullah S, Adya R, Kaur J, Heutling D, et al. Insulin and metformin regulate circulating and adipose tissue chemerin. Diabetes 2009;58:1971-1977